What is a racemate?

A racemate, also known as a racemic mixture, consists of equal amounts of two enantiomers—mirror-image forms of a chiral molecule. Because the optical rotations of the two enantiomers cancel each other out, the mixture does not rotate plane-polarised light and is therefore optically inactive. Racemates are frequently produced in non-stereoselective chemical reactions, particularly in industrial synthesis where chiral control is not implemented.

How does racemisation occur?

Racemisation refers to the process by which a pure enantiomer converts into a racemate. This can happen through various mechanisms, including acid- or base-catalysed interconversion of chiral centres, or via transient planar intermediates such as carbocations or carbanions. In pharmaceuticals, racemisation can compromise drug efficacy and safety, as one enantiomer may be therapeutically active while the other is inactive or even toxic.

Why is separating racemates important in pharmaceuticals?

In drug development, enantiomeric purity is critical. Regulatory agencies such as the MHRA, EMA, and FDA require rigorous characterisation of chiral drugs. Separating racemates into individual enantiomers—via chiral chromatography, enzymatic resolution, or asymmetric synthesis—ensures consistent pharmacokinetics, reduced side effects, and compliance with ISO, ICH, and GHS guidelines. For example, the drug thalidomide was marketed as a racemate, but only one enantiomer was effective as a sedative, while the other caused severe birth defects.

Related concepts

Chiral resolution, enantiomeric excess (ee), optical activity, asymmetric synthesis, chiral stationary phases (CSPs), enantiomer, diastereomer, ICH Q6A, USP <1119>.